The Health Ministry in India has recommended that a compulsory licence is issued for the manufacture of Bristol-Myers Squibb’s anti-cancer drug Sprycel (dasatinib), potentially opening the door to the sale of cheaper imitations.
UK biopharmaceuticals company PolyTherics has completed a takeover of Antitope, a provider of antibody engineering and immunogenicity screening services.
The annual International Association for the Protection of Intellectual Property conference in Helsinki has been assessing the potential problems for pharmaceutical companies trying to brand their medicinal products.
Law firm Rouse has teamed up with two organisations to open the BioEconomy Academy, an initiative aimed at boosting IP use and awareness in Thailand.
The American Civil Liberties Union and other groups have submitted an amici curiae brief in support of Ambry Genetics and Gene by Gene in their patent infringement cases with Myriad Genetics Inc.
UK IP firm Marks & Clerk LLP has announced two of its attorneys will be joining the firm’s partnership.
Austria has become the first country in the EU to ratify consent to the Unified Patent Court.
US law firm Miles & Stockbridge PC has continued the expansion of its IP practice with the addition of seven lawyers and one patent agent.
Eli Lilly has begun its defence of a patent covering lung cancer drug Alimta against generic companies including Teva, Barr Laboratories and APP Pharmaceuticals.
US-based Horizon Pharma Inc agreed on August 22 to settle its patent dispute over arthritis drug Duexis with generic maker Par Pharmaceutical Companies.